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Abstract: β-Secretase (BACE-1) constitutes an important target for search of anti-Alzheimer’s 
drugs. The first inhibitors of this enzyme were peptidic compounds with high molecular 
weight and low bioavailability. Therefore, the search for new efficient non-peptidic 
inhibitors has been undertaken by many scientific groups. We started our work from the 
development of in silico methodology for the design of novel BACE-1 ligands. It was 
validated on the basis of crystal structures of complexes with inhibitors, redocking,  
cross-docking and training/test sets of reference ligands. The presented procedure of 
assessment of the novel compounds as β-secretase inhibitors could be widely used in the 
design process. 
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1. Introduction 
β-Secretase (BACE-1), also called memapsin-2, is an important target for the development of  
anti-Alzheimer’s agents [1–3]. It belongs to the group of aspartyl proteases and is engaged in 
amyloidogenic pathway due to the cleavage of amyloid precursor protein (APP) at the β-site  
(Met-1–Asp1) [4]. BACE-1 splits APP into N-terminal, soluble domain sAPPβ and C-terminal 
OPEN ACCESS 
Int. J. Mol. Sci. 2014, 15 5129 
 
 
fragment C99. A large sAPPβ fragment is released from the cells while C99 remains in the membrane 
and is then processed by γ-secretase to produce β-amyloid peptides (mainly, Aβ40 and Aβ42) [5].  
Aβ aggregates, forming toxic oligomers [6]. Alzheimer’s disease is connected with overproduction of 
Aβ, which triggers a cascade of events leading to disruption in functioning of neurons [7]. Extracellular 
plaques accumulate nearby neurites and cause their degeneration [8]. 
The first reports of BACE-1 gene knockout in mice revealed that the animals developed  
normally [9]. Further studies indicated that BACE−/− mice displayed reduced synaptic plasticity and 
myelination, as well as deficiency in cognition and emotion performance test [10,11]. Nevertheless,  
β-secretase inhibitors have been proved to diminish a level of β-amyloid in the brain of mice and thus 
may be considered as a way of treating the disease, and not just alleviation of the symptoms [12]. 
Therefore, the search for novel BACE-1 inhibitors as potential therapeutics for Alzheimer’s disease (AD) 
has been undertaken by many scientists from both academia and the pharmaceutical companies [13–18]. 
β-Secretase acts on a wide diversity of substrates but in comparison with other aspartyl proteases,  
it prefers acidic or polar residues [19]. Apart from APP and its homologues, the enzyme also cleaves 
neuregulin and the β2 subunit of voltage-gated sodium channel, which both play an essential role in 
normal functioning of the brain [20,21]. BACE-1 is highly expressed in the brain and pancreas.  
Its recycling between endosomes and the trans-Golgi network is precisely controlled [22]. β-Secretase 
is synthesized as a 501 amino acid proenzyme and requires post-translational modifications.  
Pro-BACE-1 contains a signal peptide of 23 residues, followed by a 25 amino acid prosequence,  
a large catalytic domain with two conserved motifs, which are characteristic for aspartyl proteases, and 
a single transmembrane domain followed by a 23 amino acid cytosolic domain [19]. β-Secretase shares 
about 25% sequence homology with cathepsin D and renin, and has 64% similarity with its homologue 
BACE-2 (memapsin-1) [20]. BACE-2, in comparison with BACE-1, is located primarily in the heart, 
kidney, and placenta, with very low level in the brain [23]. 
Many crystal structures of BACE-1, including the apo form, complexes with large-size peptic 
ligands and with rather small inhibitors, have been obtained (Figure 1) [24]. The first X-ray structure 
of the extracellular domain complexed with a peptide inhibitor OM99-2 was reported by Hong [25]. 
This compound possesses an unnatural hydroxyethylene linker which can mimic a transition state.  
The initial BACE-1 inhibitors such as OM99-2 were peptidomimetic compounds characterized by high 
molecular weight and their structure contained a secondary alcohol group that formed hydrogen bonds 
with the catalytic dyad. The enzyme catalytic domain is composed of two aspartyl protease motifs: 
DTGS and DSGT [26,27]. The active-site aspartate residues (Asp32 and Asp228) are co-planar and in 
apo form create H-bond network with a single water molecule between them. This water is responsible 
for initiation of nucleophilic attack on the peptide carbonyl group upon substrate binding [28].  
The residues 67–77 occur in a β-hairpin conformation and are located over the active site, forming the 
flap [29]. The flap opens during the substrate entry, closes at the catalysis step and reopens to release 
the products of hydrolysis. Crystallographic studies revealed that peptidic inhibitors bind with  
β-secretase in a closed-flap form. Comparing the ligand free and ligand bound enzyme, it was observed 
that the flap adopts an open and a closed conformation, respectively. Residues 9–14 create a short loop 
between two β-strands at the base of the S3 pocket [30]. The conformation of this 10s loop also shows 
significant differences. BACE-1 also contains three disulfide bridges in the catalytic domain, which are 
essential for the correct folding and enzymatic activity [26,31]. 
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According to Schlechter and Berger’s nomenclature, four residues on both sides of the cleavage site 
of APP are called P4–P4' (P4, P3, P2, P1 ↓ P1', P2', P3', P4') [32], and the areas of enzyme which 
interact with substrate residues are named S4–S4', respectively. Recently, the crystal structure of a 
potent inhibitor OM03-4, bound to β-secretase, revealed the presence of three extra subsites  
(S5–S7) [33,34]. The superimposition of BACE-1 and cathepsin D displays significant differences in 
the structure of the S1'/S3' pocket and may be utilized to obtain the selectivity [24]. 
Figure 1. (a) Structure of β-secretase. The most important elements such as two catalytic 
aspartates, flap and 10s loop are highlighted in red and green; and (b) surface of the 
enzyme with selected subsites S4–S4' (color codes: S4S3S2S1S1'S2'S3'S4'). 
  
(a) (b) 
Significant efforts have been undertaken to identify low molecular weight, blood–brain barrier 
(BBB) penetrable, specific and stable non-peptide β-secretase inhibitors which could be developed as 
potential and effective anti-Alzheimer’s agents [35–37]. The aim of the presented studies was to 
propose a new in silico method for design and assessment of non-peptidic inhibitors of BACE-1. This 
method was based on docking procedure and validated on the basis of reference compounds from the 
literature data. Herein, we present the description and validation of the method. 
2. Results and Discussion 
The development of an effective method for the design of novel ligands requires assessment of this 
approach before it is widely used. In our case, we started from selection of the most suitable structure 
of BACE-1 for docking, which enables the best prediction of binding mode, and later we looked for 
the best scoring function to precisely predict the activity. 
2.1. Analysis of Selected Crystal Structures 
2.1.1. β-Secretase (BACE-1) 
The Protein Data Bank (PDB) [38] currently contains almost 300 crystal structures of BACE-1. 
Among them, 20 high-resolution complexes (<2.11 Å) with potent and moderately potent, peptidic and 
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non-peptidic inhibitors were selected for the analysis. As the ligand binding is dependent on the 
conformation of active site residues, special attention was paid to catalytic dyad (Asp32, Asp228),  
10s loop composed of residues 9–14, flap consisting of amino acids 67–77 and all other residues 
within 8 Å from aspartates. The root-mean-square deviation (RMSD) values for all heavy atoms of 
such defined binding site ranged from 0.18 to 2.56 Å (Figure 2 and Table S1). Visual inspection 
showed the relative rigidity of almost whole selected residues except the amino acids building the flap 
and 10s loop, which had the largest contribution in RMSD values. The position of catalytic aspartates 
did not change in a significant way. The flap occurred in three different positions upon ligand binding. 
The closed conformation was dominant but close to open form (2OHQ, 2QU3, 4ACX, 4B1D) and 
transition form between these two (3L5E, 3OHH) also appeared. The 10s loop moved forward and 
backward to change the volume of active site and adopted one of a few positions with the most 
frequent position at the bottom. Comparison of crystal structures revealed no significant correlation 
between movements of the flap and 10s loop. 
Figure 2. Matrix plot for root-mean-square deviation (RMSD) analysis. RMSD values are 
calculated for all heavy atoms of catalytic dyad, flap, 10s loop and residues within 8 Å 
from aspartates. 
 
2.1.2. Water Molecules in Crystal Structures 
The water molecules in the vicinity of the catalytic dyad play an important role in the hydrolysis of 
peptide bonds by the β-secretase. It is also known that the presence of water affects the amount of 
hydrogen bonds which may occur between the ligand and amino acids in the enzyme active site.  
The analysis of 20 complexes included all waters present in the space within 8 Å from each ligand.  
It was noted that BACE-1 active center had contained from 15 to 57 solvent molecules, at the same 
time 0–8 waters interacted with the inhibitor (Table S2). There were eight crystal structures which 
comprised water interacting with at least one catalytic aspartate. The solvent molecules, which were 
found to create hydrogen bonds with the ligand, were later taken into account during validation of the 
docking procedure. 
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2.2. Validation of Docking with Gold Suite 
2.2.1. Redocking 
In the first step of validation redocking, 20 previously mentioned complexes from PDB were used 
to check if Gold program [39] was able to reproduce original ligand poses. Hermes, the graphical user 
interface for Gold, was utilized to prepare the protein and to optimize the settings of docking. Seven 
hundred and twenty dockings, ten runs each, were performed. Three different sizes of binding site 
were tested due to the significant differences in the molecular volume of reference inhibitors.  
The active center was sequentially defined as all residues within 8, 10 and 12 Å from ligand molecule. 
In order to test the effect of water molecules, each docking was carried out with on, toggle and off 
options with regard to waters (Table S2). Four available scoring functions were evaluated to select the 
best poses. The results were analyzed and assessed in respect of run convergence and RMSD, which 
should receive the lowest value for the pose with the highest score. 
The summary of redockings is presented in Table 1. The values of selected parameters were 
established for each complex to obtain the ligand pose which was the closest to the one in crystal.  
The shown settings of docking enabled us to get 10 complexes with good poses (RMSD ≤ 1.0 Å),  
7 complexes with close poses (1 Å < RMSD ≤ 2 Å) and 3 with bad poses (RMSD > 3 Å). The worst 
poses were predicted for peptidic inhibitors from 1FKN, 1M4H and 1TQF crystal structures. It should 
be emphasized that Gold could not provide good or close poses for peptidic ligands of large flexibility, 
using basic functions. Application of constraints and interaction motifs was a solution for this problem 
but we did not want to introduce that kind of limitation. It was noted that GoldScore was the best 
scoring function in case of 13 complexes, and water was not necessary for docking in the case of  
17 structures. Only in case of three complexes (2VNN, 3L5E, 4ACX), were RMSD values slightly 
better with water than without it. The different sizes of the active site were distributed similarly. 
Table 1. Optimal settings of Gold for redockings of 20 reference inhibitors. 










1FKN OM99-2 A 12 ChemPLP 101.86 3.94 no 
1M4H OM00-3 A 8 GoldScore 113.00 4.84 no 
1TQF 32P A 10 GoldScore 92.02 3.60 no 
2B8L 5HA A 12 GoldScore 133.76 0.65 no 
2F3F BDF488 C 12 ASP 54.23 0.31 no 
2IQG 2FI A 10 ASP 54.87 1.13 no 
2OAH QIN A 8 ChemPLP 129.36 1.22 no 
2OHQ 7IP A 12 GoldScore 72.57 0.20 no 
2QP8 SCH734723 A 8 GoldScore 97.51 1.43 no 
2QU3 462 A 12 GoldScore 67.69 1.01 no 
2QZL IXS A 10 GoldScore 116.81 1.15 no 
2VNM CM8 A 12 GoldScore 113.13 0.81 no 
2VNN CM7 A 8 ChemScore 52.00 0.47 yes 
2ZJM F1M A 8 GoldScore 96.86 0.64 no 
3CIC SCH709583 A 10 GoldScore 114.20 1.27 no 
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Table 1. Cont. 










3L5E SCH736062 A 8 GoldScore 77.80 1.00 yes 
3OHH BMS681889 A 10 GoldScore 99.81 1.99 no 
4ACX S82 A 10 ChemPLP 99.61 0.51 yes 
4B1D 6TG A 10 ChemScore 32.00 0.27 no 
4D8C NVP-BXD552 C 10 GoldScore 102.69 0.95 no 
* Original symbols of ligands were provided if available, otherwise symbols from PDB complexes. 
2.2.2. Cross-Docking 
According to the results of previous step, the enzyme structures from the top 10 complexes with the 
lowest RMSD value and all 17 non-peptidic inhibitors were selected for the cross-dockings. Each 
inhibitor was docked to the enzyme from each complex, using settings from Table 1 with respect to the 
protein. The quality of fit was evaluated on the basis of ligand RMSD values with the following 
ranges: RMSD ≤ 1.0 Å for good pose, 1 Å < RMSD ≤ 2 Å for close pose, 2 Å < RMSD ≤ 3 Å for pose 
with errors and RMSD > 3 Å for bad pose. The plot presenting the results of cross-docking is shown in 
the Figure 3 (see also Table S3). 
Figure 3. Matrix plot for RMSD analysis of ligand poses upon cross-docking. 
 
It was noted that among 10 β-secretase structures, 4D8C and 3L5E were the most suitable for the 
docking due to the highest number of well adopted ligands. The first one, 4D8C, was BACE-1 with 
closed conformation of flap. It could adopt eight inhibitors, resulting in good and close poses. 
Moreover, the docking did not require any water molecules inside active center. Unfortunately, the 
ligands, which were naturally bound with unclosed flap BACE-1, docked to this structure with higher 
RMSD values, e.g., ligands from 3L5E or 3OHH. The second structure (3L5E) was the enzyme with 
transition state of the flap, and during the docking to this structure the water molecules were necessary 
to obtain the right binding mode. In this case, seven good and close poses were received. 
Based on those findings, we selected the structure of β-secretase from 4D8C complex for further 
studies due to the close conformation of flap and docking without water. 




It is very important to predict the activity correctly during the design of novel ligands. Therefore, 
we decided to examine the relationship between scoring function and the biological activity for a group 
of reference inhibitors. The ligand poses, in case of docking to the selected 4D8C structure, were 
finally assessed by GoldScore and we wanted to know if this scoring function was accurate enough or 
the results required rescoring. The previous set of non-peptidic ligands could not be used directly 
because it contained only 17 derivatives. Moreover, their activity was determined in different assays 
and should not be compared without standardization. Therefore, a novel group of 60 inhibitors was 
selected on the basis of literature data [40–45]. All compounds were tested in the assay, based on 
fluorescence resonance energy transfer (FRET) technique and using Rh-EVNLDAEFK-Quencher as 
substrate of BACE-1. They were structurally diverse and belonged to different chemical groups: 
aminopyridines, coumarines, flavonoids, diterpenoids, aminopropanoles, biaryls and fused-rings. The 
potency of these compounds was in a wide range of IC50 values: 56 nM–2 mM. (Table S4). 
The prepared library of reference inhibitors was divided into two subgroups: training set and test set 
(Figure 4). Both sets of ligands were docked into β-secretase but the first one was used to establish a 
relationship between score and activity, expressed as pIC50; meanwhile, the second one was utilized to 
test the predictability of the potency by the method. 
Figure 4. Plot of score vs. experimental pIC50 for the training and test set of reference 
inhibitors. Each set contains 30 compounds (blue marks: training set; and red marks: test set). 
 
The statistically significant correlation between GoldScore and pIC50 was observed for the training 
set. Equation (1) describes this relationship. It is characterized by high correlation coefficient  
(R = 0.8822, n = 30). 
pIC50 = 0.0791 × GoldScore + 0.410 (1) 
In the next step, the activity of the test set was predicted, based on GoldScore from docking and 
Equation 1, developed for the training set. It was observed that predicted values were highly correlated 
with experimental ones (R = 0.8937, n = 30, Figure 5 and Table 2), and the errors for prediction of 
pIC50 were really low for such kind of procedure. Indeed, the method enabled to differentiate 
compounds of high, moderate and low activity and can be used in the search of novel non-peptidic 
BACE-1 inhibitors. Docking to 4D8C β-secretase structure and assessment by GoldScore was 
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especially advantageous because this scoring function gave accurate values and no rescoring was 
needed. The presented method could be useful in both virtual screening and fragment-based design of 
new potential BACE-1 inhibitors. 
Figure 5. Correlation between predicted and experimental values of the activity for the test 
set (R = 0.8937, n = 30). 
 
Table 2. Comparison of predicted and experimental activities for the test set. Compounds 

















1 76.74 6.48 7.20 −0.72 16 65.78 5.61 5.30 0.31 
2 74.07 6.27 7.00 −0.73 17 59.32 5.10 5.05 0.06 
3 74.15 6.28 6.95 −0.68 18 66.03 5.63 5.00 0.63 
4 72.20 6.12 6.92 −0.80 19 61.99 5.31 5.00 0.31 
5 72.49 6.14 6.82 −0.68 20 48.90 4.28 4.73 −0.45 
6 70.94 6.02 6.82 −0.80 21 46.12 4.06 4.63 −0.57 
7 67.61 5.76 6.62 −0.86 22 50.47 4.40 4.62 −0.22 
8 76.82 6.49 6.55 −0.06 23 50.96 4.44 4.41 0.03 
9 72.70 6.16 6.28 −0.12 24 43.23 3.83 4.38 −0.55 
10 77.07 6.51 6.13 0.38 25 46.15 4.06 4.21 −0.15 
11 78.03 6.58 6.05 0.53 26 53.70 4.66 4.03 0.63 
12 70.10 5.96 5.96 0.00 27 45.37 4.00 4.00 0.00 
13 78.88 6.65 5.90 0.75 28 43.96 3.89 4.00 −0.11 
14 64.45 5.51 5.78 −0.27 29 47.96 4.20 3.51 0.70 
15 54.23 4.70 5.55 −0.85 30 40.10 3.58 2.70 0.88 
pred. means predicted; and exp. means experimental. 
3. Experimental Section 
3.1. Analysis of Selected Crystal Structures 
The 20 crystal structures of human β-secretase were obtained from Protein Data Bank [38], and 
their codes are shown in Table 1. Mutual complex comparison was performed with PyMol 0.99rc2 
(DeLano Scientific LLC., Palo Alto, CA, USA) [46] and Sybyl X 1.2 (Tripos, St. Louis, MO, USA) [47] 
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programs. In case of oligomeric structure of BACE-1, one monomer was selected (Table 1) and used in 
further analyses. The interactions between enzyme, ligand and water in each complex were checked by 
LigX module, implemented in MOE 2009.10 (Chemical Computing Group, Montreal, QC, Canada) [48]. 
3.2. Docking and Scoring 
The 3D structures of all ligands were created by Corina on-line [49] and saved as PDB files. Using 
Sybyl X 1.2, atom types were checked, protonation states were assigned, missing hydrogen atoms were 
added and Gasteiger-Marsili charges were assigned. Finally, the compound structures were saved in 
mol2 format. 
During the protein preparation, all histidine residues were protonated at Nε, the hydrogen atoms 
were added and ligand molecules were removed. The binding site was sequentially defined as all 
amino acid residues within 8, 10 or 12 Å from original ligand. Some water molecules (specified in 
Table S2) were taken into account (on, toggle, off). Dockings were performed with Gold 5.1  
(The Cambridge Crystallographic Data Centre, Cambridge, UK) [39]. A standard set of genetic 
algorithm with a population size of 100, a number of operations of 100,000 and clustering with a 
tolerance of 1 Å was applied. All scoring functions (GoldScore, ChemScore, ChemPLP, ASP) were 
tested for the evaluation of the docking results. For each ligand, the final results involved 10 poses, 
arranged on the ranking list, according to the scoring function values. 
The best settings of docking to each selected crystal structure are listed in the Table 1. 
4. Conclusions 
Performed in silico analyses allowed us to propose the methodology for the design of novel  
non-peptidic potential inhibitors of β-secretase. It was fully validated and it was shown that the 
predictions were accurate. Based on redocking and cross-docking, among 20 crystal structures the 
most suitable complex was selected for the prediction of the binding mode. The structure 4D8C 
adopted many ligands correctly and the most importantly, the water molecules did not have to be taken 
into account during the docking. This made the method easier and faster. The group of 60 ligands, 
divided into two sets, enabled to check the relationship between the scoring function and the activity. 
The high correlation was found, and the regression equation was determined. Finally, it was proved 
that the method predicted the activity of test set precisely. 
Further studies for verification this approach by synthesis of novel compounds and biological 
evaluation as potential BACE1 inhibitors are in progress. 
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